Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.

Saved in:
Bibliographic Details
Title: Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Authors: Chang JY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jychang@mdanderson.org., Lin SH; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dong W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liao Z; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gandhi SJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gay CM; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chun SG; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elamin YY; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fossella FV; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Blumenschein G; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cascone T; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le X; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pozadzides JV; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsao A; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Verma V; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Welsh JW; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen AB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Altan M; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mehran RJ; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vaporciyan AA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Swisher SG; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Balter PA; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fujimoto J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heymach JV; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Lancet (London, England) [Lancet] 2023 Sep 09; Vol. 402 (10405), pp. 871-881. Date of Electronic Publication: 2023 Jul 18.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(23)01384-3